D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Investing.com -- Dianthus Therapeutics (NASDAQ:DNTH) stock rose 5.8% after receiving its 13th buy rating, with William Blair analyst Mylers Minter initiating coverage with an Outperform rating.
The clinical-stage biotech company, which is developing DNTH103, an active C1s monoclonal antibody for autoimmune neuromuscular indications, saw its shares climb following the positive analyst assessment. Minter assigned a fair value of $47.57 per share to the stock.
"We are initiating coverage of Dianthus Therapeutics with an Outperform rating and fair value of $47.57 per share. Dianthus is a clinical-stage biotech company developing DNTH103, an active C1s monoclonal antibody, for autoimmune neuromuscular indications. Risks to an investment are primarily clinical, regulatory, and commercial in nature, similar to other biotechnology companies," Minter stated in his initiation note.
The latest coverage adds to Dianthus Therapeutics’ impressive analyst sentiment, with the company now boasting 13 buy ratings and no hold or sell recommendations from Wall Street analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.